TRUPANION, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24 USD | -0.50% |
|
+7.38% | -21.34% |
| 04-22 | Trupanion Introduces truInsights: A Pet Health Data Initiative | CI |
| 04-05 | Piper Sandler Cuts Price Target on Trupanion to $28 From $32, Maintains Overweight Rating | MT |
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.34% | 1.01B | C | ||
| +11.81% | 9.51B | B- | ||
| 0.00% | 6.5B | C+ | ||
| +90.16% | 4.12B | - | ||
| +0.81% | 2.39B | B+ | ||
| +2.70% | 876M | - | D+ | |
| +83.33% | 739M | - | C | |
| +3.52% | 155M | - | - | |
| -6.42% | 70.04M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- TRUP Stock
- Ratings Trupanion, Inc.
